Full Breakdown
Legal Battle Over Cancer Treatment Coverage: Pablo Langesfeld vs. Oscar Health Insurance
4/8/2026, 1:48:26 PM
Overview of the Case
Pablo Langesfeld, a 60-year-old resident of Doral, Florida, is engaged in a legal dispute with Oscar Health Insurance over the denial of coverage for a cancer treatment he urgently needs. Langesfeld, who is battling advanced pancreatic cancer that has metastasized to his liver, has been prescribed a drug therapy called Avmapki Fakzynja Co Pack. The treatment, which costs approximately $48,500 every three weeks, has been deemed medically necessary by his doctors but rejected by the insurer on the grounds that it is not federally approved for his specific type of cancer.
Background on the Treatment
Avmapki Fakzynja, a combination of avutometinib and defactinib, is FDA-approved for ovarian cancer and received an "orphan drug" designation in 2024 to promote research for pancreatic cancer, which is the third-leading cause of cancer-related deaths in the U.S. The manufacturer, Verastem Oncology, reports promising trial results for this treatment in patients with metastatic pancreatic cancer, a condition affecting over 30,000 individuals annually in the U.S.
Legal Proceedings and Implications
The case is currently before Miami-Dade Circuit Judge Migna Sanchez-Llorens, who is expected to rule on whether Oscar Health Insurance must cover the treatment. A jury recently sided with Langesfeld, affirming the appropriateness of the prescribed therapy in four out of five questions posed during the trial. Langesfeld's attorney, Maria Santi, expressed confidence in the judge's forthcoming decision, citing substantial evidence supporting the medication's medical necessity.
Insurance Policy and Coverage Disputes
Langesfeld's legal team argues that Oscar Health's denial contradicts its own policy, which stipulates coverage for chemotherapy drugs and medically necessary treatments that are FDA-approved or supported by scientific literature. However, insurance companies often label unapproved uses of drugs as "experimental," leading to coverage denials. This practice raises concerns about patient access to potentially life-saving treatments.
Family's Perspective and Ongoing Struggles
Langesfeld's family, particularly his son Martin, has voiced frustration over the insurance battle. Martin stated, "We are just asking for simple approval. It shouldn’t be this big of a fight." Currently, Langesfeld is undergoing weekly chemotherapy sessions while waiting for a resolution regarding the additional drug therapy, which he has been unable to access due to the ongoing dispute.
Conflicting Reports & Gaps
While the jury has ruled in favor of Langesfeld regarding the appropriateness of the drug therapy, Oscar Health Insurance has not publicly commented on the case, leaving questions about their rationale for the denial. The lack of transparency from the insurer adds to the uncertainty surrounding the case.
Verbatim Quotes
- “Fighting cancer is already overwhelming — the toll of chemotherapy is brutal. But battling insurance denials at the same time makes it unbearable and incredibly stressful for me and my family,” — Pablo Langesfeld
- “There is abundant evidence that this medication is medically necessary for Pablo,” — Maria Santi, Attorney
- “Every day he waits is another day without medication,” he said.” — Martin Langesfeld
This case highlights the ongoing challenges patients face in securing insurance coverage for necessary medical treatments, particularly in the context of serious illnesses like cancer. The outcome of Langesfeld's lawsuit may have broader implications for similar cases in the future.
